Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Sell
22
ELV Quote, Financials, Valuation and Earnings
Last price:
$366.21
Seasonality move
:
3.48%
Day range:
$364.86 - $372.00
52-week range:
$362.21 - $567.26
Dividend yield:
1.78%
P/E ratio:
13.34x
P/S ratio:
0.49x
P/B ratio:
1.94x
Volume:
3.4M
Avg. volume:
2M
1-year change:
-20.31%
Market cap:
$84.9B
Revenue:
$171.3B
EPS (TTM):
$27.43
Analysts' Opinion
-
Consensus RatingElevance Health has received a consensus rating of Buy. The company's average rating is a Buy based on 14 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $508.08, Elevance Health has an estimated upside of 38.83% from its current price of $365.96.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $388.00 representing -6.02% downside risk from its current price of $365.96.
Fair Value
-
According to the consensus of 18 analysts, Elevance Health has 38.83% upside to fair value with a price target of $508.08 per share.
ELV vs. S&P 500
-
Over the past 5 trading days, Elevance Health has underperformed the S&P 500 by -2.11% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Elevance Health does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Elevance Health has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Elevance Health reported revenues of $45.1B.
Earnings Growth
-
Elevance Health earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Elevance Health reported earnings per share of $4.36.
Enterprise value:
75.3B
EV / Invested capital:
1.06x
Price / LTM sales:
0.49x
EV / EBIT:
8.01x
EV / Revenue:
0.43x
PEG ratio (5yr expected):
1.73x
EV / Free cash flow:
86.46x
Price / Operating cash flow:
98.35x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
5.72%
Net Income Margin (TTM):
3.69%
Return On Equity:
15.67%
Return On Invested Capital:
9.55%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $153.2B | $168.6B | $174B | $42.8B | $45.1B | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | $25.30 | $25.47 | $27.43 | $5.45 | $4.36 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $38.2B | $44.6B | $48.6B | $55.7B | $55.2B | |
| Total Assets | $86.6B | $98.1B | $103B | $110.5B | $116.5B | |
| Current Liabilities | $18.5B | $21.5B | $26.4B | $27.3B | $25.9B | |
| Total Liabilities | $52.7B | $62.3B | $67B | $71.9B | $72.7B | |
| Total Equity | $33.9B | $35.8B | $36B | $38.5B | $43.9B | |
| Total Debt | $20.8B | $22.8B | $23.8B | $24.8B | $27.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $11.6B | $9.5B | $2.1B | $2.6B | $2.7B | |
| Cash From Investing | -$5.8B | -$4.3B | -$4.6B | -$687M | -$401M | |
| Cash From Financing | -$2.4B | -$3.2B | -$609M | -$994M | -$915M | |
| Free Cash Flow | $10.4B | $8.2B | $871M | $2.3B | $2.3B | |
ELV
Sector
Market Cap
$84.9B
$44.6M
Price % of 52-Week High
64.51%
45.71%
Dividend Yield
1.78%
0%
Shareholder Yield
2.56%
-0.68%
1-Year Price Total Return
-20.31%
-29.09%
Beta (5-Year)
0.828
0.772
Dividend yield:
1.78%
Annualized payout:
$5.92
Payout ratio:
23.08%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$372.96
200-day SMA
Sell
Level
$498.65
Bollinger Bands (100)
Sell
Level
406.39 - 537.35
Chaikin Money Flow
Buy
Level
138.6M
20-day SMA
Sell
Level
$389.23
Relative Strength Index (RSI14)
Sell
Level
28.86
ADX Line
Sell
Level
9.18
Williams %R
Buy
Level
-92.5197
50-day SMA
Sell
Level
$411.63
MACD (12, 26)
Sell
Level
-14.05
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Sell
Level
-10.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.4997)
Buy
CA Score
(Annual)
Level (-0.1133)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-1.1204)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Elevance Health remains one of the leading health insurers in the U.S., providing medical benefits to 47 million medical members as of December 2023. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs such as Medicaid and Medicare Advantage plans, too.
Stock Forecast FAQ
In the current month, ELV has received 14 Buy ratings 4 Hold ratings, and 0 Sell ratings. The ELV average analyst price target in the past 3 months is $508.08.
-
Where Will Elevance Health Stock Be In 1 Year?
According to analysts, the consensus estimate is that Elevance Health share price will rise to $508.08 per share over the next 12 months.
-
What Do Analysts Say About Elevance Health?
Analysts are divided on their view about Elevance Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Elevance Health is a Sell and believe this share price will drop from its current level to $388.00.
-
What Is Elevance Health's Price Target?
The price target for Elevance Health over the next 1-year time period is forecast to be $508.08 according to 18 Wall Street analysts, 14 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is ELV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Elevance Health is a Buy. 14 of 18 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ELV?
You can purchase shares of Elevance Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Elevance Health shares.
-
What Is The Elevance Health Share Price Today?
Elevance Health was last trading at $366.21 per share. This represents the most recent stock quote for Elevance Health. Yesterday, Elevance Health closed at $365.96 per share.
-
How To Buy Elevance Health Stock Online?
In order to purchase Elevance Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Lucid vs Rivian Stock: Which Is Best?
Few realize that Lucid Group (NASDAQ: LCID) traces part of…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
